Showing results (311-320 of 333) with videos related to
Sort By:
Pageof 34
NPJ Precision Oncology|July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair systemKai Zimmer, Florian Kocher, Gerold Untergasser, et al.Blood|September 13, 2019
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsTata Nageswara Rao, Nils Hansen, Julian Hilfiker, et al.Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.The Lancet. Respiratory Medicine|June 14, 2021
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Michael Schreinlechner, Nikolay Sappler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.Journal of Hematology & Oncology|April 3, 2023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registryFrancesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, et al.Nature Communications|August 30, 2024
Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfateElena Ethel Vidal-Calvo, Anne Martin-Salazar, Swati Choudhary, et al.Pageof 34